Right Dose, Right Now: Customized Drug Dosing in the Critically Ill

被引:53
作者
Roberts, Jason A. [1 ,2 ,3 ,4 ]
Kumar, Anand [5 ,6 ,7 ,8 ,9 ,10 ]
Lipman, Jeffrey [1 ,2 ]
机构
[1] Univ Queensland, Sch Med, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[2] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
[4] Univ Queensland, Sch Pharm, Ctr Translat Antiinfect Pharmacodynam, Brisbane, Qld, Australia
[5] Univ Manitoba, St Boniface Hosp, Dept Med, Hlth Sci Ctr,Sect Critical Care Med, Winnipeg, MB, Canada
[6] Univ Manitoba, St Boniface Hosp, Dept Med, Hlth Sci Ctr,Sect Infect Dis, Winnipeg, MB, Canada
[7] Univ Manitoba, St Boniface Hosp, Dept Med Microbiol, Hlth Sci Ctr,Sect Critical Care Med, Winnipeg, MB, Canada
[8] Univ Manitoba, St Boniface Hosp, Dept Med Microbiol, Hlth Sci Ctr,Sect Infect Dis, Winnipeg, MB, Canada
[9] Univ Manitoba, St Boniface Hosp, Dept Pharmacol, Hlth Sci Ctr,Sect Critical Care Med, Winnipeg, MB, Canada
[10] Univ Manitoba, St Boniface Hosp, Dept Pharmacol, Hlth Sci Ctr,Sect Infect Dis, Winnipeg, MB, Canada
关键词
antibiotics; intensive care; pharmacodynamics; pharmacokinetics; sepsis; EMPIRIC ANTIBIOTIC-TREATMENT; BETA-LACTAM ANTIBIOTICS; CARE-UNIT PATIENTS; SEVERE SEPSIS; CONTINUOUS-INFUSION; SEPTIC SHOCK; CLINICAL PHARMACODYNAMICS; ANTIMICROBIAL THERAPY; INHIBITORY CURVE; VANCOMYCIN;
D O I
10.1097/CCM.0000000000002210
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Drugs are key weapons that clinicians have to battle against the profound pathologies encountered in critically ill patients. Antibiotics in particular are commonly used and can improve patient outcomes dramatically. Despite this, there are strong opportunities for further reducing the persisting poor outcomes for infected critically ill patients. However, taking these next steps for improving patient care requires a new approach to antibiotic therapy. Giving the right dose is highly likely to increase the probability of clinical cure from infection and suppress the emergence of resistant pathogens. Furthermore, in some patients with higher levels of sickness severity, reduced mortality from an optimized approach to antibiotic use could also occur. To enable optimized dosing, the use of customized dosing regimens through either evidence-based dosing nomograms or preferably through the use of dosing software supplemented by therapeutic drug monitoring data should be embedded into daily practice. These customized dosing regimens should also be given as soon as practicable as reduced time to initiation of therapy has been shown to improve patient survival, particularly in the presence of septic shock. However, robust data supporting these logical approaches to therapy, which may deliver the next step change improvement for treatment of infections in critically ill patients, are lacking. Large prospective studies of patient survival and health system costs are now required to determine the value of customized antibiotic dosing, that is, giving the right dose at the right time.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 51 条
  • [1] Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
    Abdul-Aziz, Mohd H.
    Sulaiman, Helmi
    Mat-Nor, Mohd-Basri
    Rai, Vineya
    Wong, Kang K.
    Hasan, Mohd S.
    Abd Rahman, Azrin N.
    Jamal, Janattul A.
    Wallis, Steven C.
    Lipman, Jeffrey
    Staatz, Christine E.
    Roberts, Jason A.
    [J]. INTENSIVE CARE MEDICINE, 2016, 42 (10) : 1535 - 1545
  • [2] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [3] Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy
    Bagshaw, Sean M.
    Lapinsky, Stephen
    Dial, Sandra
    Arabi, Yaseen
    Dodek, Peter
    Wood, Gordon
    Ellis, Paul
    Guzman, Jorge
    Marshall, John
    Parrillo, Joseph E.
    Skrobik, Yoanna
    Kumar, Anand
    [J]. INTENSIVE CARE MEDICINE, 2009, 35 (05) : 871 - 881
  • [4] Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study
    Blot, Stijn
    Koulenti, Despoina
    Akova, Murat
    Bassetti, Matteo
    De Waele, Jan J.
    Dimopoulos, George
    Kaukonen, Kirsi-Maija
    Martin, Claude
    Montravers, Philippe
    Rello, Jordi
    Rhodes, Andrew
    Starr, Therese
    Wallis, Steven C.
    Lipman, Jeffrey
    Roberts, Jason A.
    [J]. CRITICAL CARE, 2014, 18 (03):
  • [5] Intravenous colistin in a patient with serious burns and borderline syndrome: The benefits of therapeutic drug monitoring
    Bode-Boeger, Stefanie M.
    Schopp, Brigitte
    Troeger, Uwe
    Martens-Lobenhoffer, Jens
    Kalousis, Konstantin
    Mailaender, Peter
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (04) : 357 - 360
  • [6] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
  • [7] New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients
    Cristallini, Stefano
    Hites, Maya
    Kabtouri, Hakim
    Roberts, Jason A.
    Beumier, Marjorie
    Cotton, Frederic
    Lipman, Jeffrey
    Jacobs, Frederique
    Vincent, Jean-Louis
    Creteur, Jacques
    Taccone, Fabio Silvio
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) : 4750 - 4756
  • [8] The association between time to antibiotics and relevant clinical outcomes in emergency department patients with various stages of sepsis: a prospective multi-center study
    de Groot, Bas
    Ansems, Annemieke
    Gerling, Daan H.
    Rijpsma, Douwe
    van Amstel, Paul
    Linzel, Durk
    Kostense, Piet J.
    Jonker, Marianne
    de Jonge, Evert
    [J]. CRITICAL CARE, 2015, 19
  • [9] Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
    Drusano, GL
    [J]. NATURE REVIEWS MICROBIOLOGY, 2004, 2 (04) : 289 - 300
  • [10] A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis
    Dulhunty, Joel M.
    Roberts, Jason A.
    Davis, Joshua S.
    Webb, Steven A. R.
    Bellomo, Rinaldo
    Gomersall, Charles
    Shirwadkar, Charudatt
    Eastwood, Glenn M.
    Myburgh, John
    Paterson, David L.
    Starr, Therese
    Paul, Sanjoy K.
    Lipman, Jeffrey
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (11) : 1298 - 1305